Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?

References

• Centers for Disease Control and Prevention. Clostridioides difficile infection. Available from: https://www.cdc.gov/media/releases/2015/p0225-clostridium-difficile.html. Accessed February 21, 2023.
   Google Scholar
• Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825–834. doi:10.1056/NEJMoa1408913
   PubMed Web of Science ®Google Scholar
• Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999–2007. Clin Infect Dis. 2012;55(2):216–223. doi:10.1093/cid/cis386
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. CDC Healthcare Associated Infections: Clostridiodes difficile infection. Available from: https://www.cdc.gov/hai/organisms/cdiff/cdiff_infect.html. Accessed February 21 21, 2023.
   Google Scholar
• Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3:31. doi:10.1186/s40168-015-0094-5
   PubMed Web of Science ®Google Scholar
• Gordon J, Knowlton N, Relman DA, Rohwer F, Youle M. Superorganisms and holobionts. Microbe. 2013;8(4):152–153.
   Google Scholar
• Foster KR, Schluter J, Coyte KZ, Rakoff-Nahoum S. The evolution of the host microbiome as an ecosystem on a leash. Nature. 2017;548(7665):43–51. doi:10.1038/nature23292
   PubMed Web of Science ®Google Scholar
• Dawkins JJ, Allegretti JR, Gibson TE, et al. Gut metabolites predict Clostridioides difficile recurrence. Microbiome. 2022;10(1):87. doi:10.1186/s40168-022-01284-1
   PubMed Web of Science ®Google Scholar
• Crobach MJT, Ducarmon QR, Terveer EM, et al. The bacterial gut microbiota of adult patients infected, colonized or noncolonized by Clostridioides difficile. Microorganisms. 2020;8(5):677. doi:10.3390/microorganisms8050677
   PubMed Web of Science ®Google Scholar
• Robinson JI, Weir WH, Crowley JR, et al. Metabolomic networks connect host-microbiome processes to human Clostridioides difficile infections. J Clin Invest. 2019;129(9):3792–3806. doi:10.1172/JCI126905
   PubMed Web of Science ®Google Scholar
• Ajami NJ, Cope JL, Wong MC, Petrosino JF, Chesnel L. Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to Clostridium difficile colonization in mice. Antimicrob Agents Chemother. 2018;62(5). doi:10.1128/aac.02112-17
   PubMed Web of Science ®Google Scholar
• Thorpe CM, Kane AV, Chang J, Tai A, Vickers RJ, Snydman DR. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin. PLoS One. 2018;13(8):e0199810. doi:10.1371/journal.pone.0199810
   PubMed Web of Science ®Google Scholar
• Okhuysen PC, Ramesh M, Garey KW, et al. 730. A Phase 3, randomized, double-blind study to evaluate the efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridioides difficile infection. Open Forum Infect Dis. 2022;9(Supplement_2). doi:10.1093/ofid/ofac492.021
   Google Scholar
• Palleja A, Mikkelsen KH, Forslund SK, et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255–1265. doi:10.1038/s41564-018-0257-9
   PubMed Web of Science ®Google Scholar
• Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854–859.
   PubMed Web of Science ®Google Scholar
• Seekatz AM, Safdar N, Khanna S. The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2022;15:17562848221134396. doi:10.1177/17562848221134396
   Web of Science ®Google Scholar
• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):987–994. doi:10.1093/cid/ciy149
   PubMed Web of Science ®Google Scholar
• Tariq R, Hayat M, Pardi D, Khanna S. Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2021;40(7):1383–1392. doi:10.1007/s10096-021-04163-z
   PubMed Web of Science ®Google Scholar
• Quraishi MN, Widlak M, Bhala N, et al. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017;46(5):479–493. doi:10.1111/apt.14201
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Guidance for Industry: Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridoides difficile infection not responsive to standard treatments. Available from: https://www.fda.gov/media/86440/download. Accessed February. 21, 2023
   Google Scholar
• US Food and Drug Administration. Guidance for Industry: Early clinical trials with live biotherapeutic products:chemistry, manufacturing, and control information. Available from: https://www.fda.gov/files/vaccines,%20blood%20%26%20biologics/published/Early-Clinical-Trials-With-Live-Biotherapeutic-Products--Chemistry--Manufacturing--and-Control-Information--Guidance-for-Industry.pdf. Accessed February 17, 2023.
   Google Scholar
• Orenstein R, Dubberke E, Hardi R, et al. Safety and Durability of RBX2660 (Microbiota Suspension) for recurrent Clostridium difficile Infection: results of the PUNCH CD study. Clin Infect Dis. 2016;62(5):596–602. doi:10.1093/cid/civ938
   PubMed Web of Science ®Google Scholar
• Orenstein R, Dubberke ER, Khanna S, et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022;22(1):245. doi:10.1186/s12879-022-07256-y
   PubMed Web of Science ®Google Scholar
• Orenstein R. The role of microbiome-based therapeutics in Clostridioides difficile infection: durable, long-term results of RBX2660. Infect Dis Ther. 2023;12(1):1–7. doi:10.1007/s40121-022-00714-9
   PubMed Web of Science ®Google Scholar
• Dubberke ER, Orenstein R, Khanna S, Guthmueller B, Lee C. Final results from a Phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection. Infect Dis Ther. 2023;12(2):703–709. doi:10.1007/s40121-022-00744-3
   PubMed Web of Science ®Google Scholar
• Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a Phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527–1538. doi:10.1007/s40265-022-01797-x
   PubMed Web of Science ®Google Scholar
• Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214(2):173–181. doi:10.1093/infdis/jiv766
   PubMed Web of Science ®Google Scholar
• McGovern BH, Ford CB, Henn MR, et al. SER-109, an investigational microbiome drug to reduce recurrence after Clostridioides difficile infection: lessons learned from a Phase 2 trial. Clin Infect Dis. 2021;72(12):2132–2140. doi:10.1093/cid/ciaa387
   PubMed Web of Science ®Google Scholar
• Feuerstadt P, Louie TJ, Lashner B, et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection. N Engl J Med. 2022;386(3):220–229. doi:10.1056/NEJMoa2106516
   PubMed Web of Science ®Google Scholar
• Khanna S, Sims M, Louie TJ, et al. SER-109: an oral investigational microbiome therapeutic for patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics. 2022;11(9):1234. doi:10.3390/antibiotics11091234
   Google Scholar
• Sims MD, Khanna S, Feuerstadt P, et al. Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a Phase 3, open-label, single-arm trial. JAMA Network Open. 2023;6(2):e2255758. doi:10.1001/jamanetworkopen.2022.55758
   PubMed Web of Science ®Google Scholar
• Khanna S, Kelly CR, Louie T, et al. S131 CP101, an Investigational orally administered microbiome therapeutic, increases intestinal microbiome diversity and prevents recurrent C. difficile Infection: results from a randomized, placebo-controlled trial. Off J Am Coll Gastroenterol. 2021;116:S57. doi:10.14309/01.ajg.0000772996.83378.7c
   PubMed Web of Science ®Google Scholar
• Allegretti J, Kelly C, Louie T. An investigational oral microbiome drug, CP101, for the prevention of recurrent C. difficile infection: a randomized, placebo-controlled, multi-center trial (PRISM3). Late Break Abstr ACG. 2020;
   Google Scholar
• Allegretti JR, Kelly CR, Fischer M, Cohen T, Budree S, Khanna S. Tu1519: CP101, an investigational microbiome therapeutic for the prevention of recurrent C. difficile infection: a combined analysis of the PRISM3 (Randomized Placebo-Controlled) and PRISM-EXT (Open-Label) trials. Gastroenterology. 2022;162(7):S-995-S–996.
   Web of Science ®Google Scholar
• ClinicalTrials.gov. A trial of CP101 for the Prevention of Recurrent CDI (PRISM4). Available from: https://clinicaltrials.gov/ct2/show/NCT05153499. Accessed February. 16, 2023
   Google Scholar
• Dsouza M, Menon R, Crossette E, et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe. 2022;30(4):583–598.e8. doi:10.1016/j.chom.2022.03.016
   PubMed Web of Science ®Google Scholar
• Bobilev D, Bhattarai S, Menon R, et al. 1953. VE303, a rationally designed bacterial consortium for prevention of recurrent Clostridioides difficile (C. difficile) infection (rCDI), Stably restores the gut microbiota after vancomycin (vanco)-induced dysbiosis in Adult Healthy Volunteers (HV). Open Forum Infect Dis. 2019;6(Suppl2):S60. doi:10.1093/ofid/ofz359.130
   Google Scholar
• Louie T, Golan Y, Khanna S, et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA. 2023;329(16):1356–1366. doi:10.1001/jama.2023.4314
   PubMed Web of Science ®Google Scholar
• Khanna S. Microbiota restoration for recurrent Clostridioides difficile: getting one step closer every day! J Intern Med. 2021;290(2):294–309. doi:10.1111/joim.13290
   PubMed Web of Science ®Google Scholar
• Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a non-frozen, orally administered investigational live biotherapeutic, is safe, effective, and shifts patients’ microbiomes in a Phase 1 study for recurrent Clostridioides difficile infections. Clin Infect Dis. 2021;73(7):e1613–e1620. doi:10.1093/cid/ciaa1430
   PubMed Web of Science ®Google Scholar